Kazuki Nozawa, MD· @kazuki_nozawa · X·· 2 days agoScore70
Body · original
PANKU-Breast01
#ESMO26
Iza-bren (EGFRxHER3-ADC) significantly improved PFS vs chemotherapy in pretreated HR+/HER2− advanced breast cancer (8.2 vs 4.0 months; HR 0.41). ORR doubled (40.5% vs 20.2%), with manageable safety (ILD 1.1%). OS remains immature.
491 views · 8 likes · 3 reposts · 0 replies
Conference abstracts
LBA50matched by Proffered paper 1: Breast cancer, early and advanced stage
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.orgSource: Kazuki Nozawa, MD · x.com